Annual LCR urine screening would cut cost of chlamydia treatment, study shows.
This article was originally published in The Gray Sheet
ANNUAL URINE SCREENING WITH LCR WOULD HALVE CHLAMYDIA TREATMENT COSTS IN U.S., according to a study presented by Max Chernesky, PhD, St. Josephs Hospital, Hamilton, Ontario, at the recent American Association of Clinical Chemistry conference in Chicago. The study, which used a computer-based economic model to analyze data from published literature, showed that instituting an annual urine screening program using a ligase chain reaction probe assay could reduce "to less than $400 mil. a year from over $1 bil." the cost of treating certain diseases caused by chlamydia.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.